Xenical labeling approved to show 42% reduction in relative risk of developing type 2 diabetes
Xenical labeling approved to show 42% reduction in relative risk of developing type 2 diabetes
NUTLEY, N.J., October 29, 2004 -- Roche announced that the FDA has approved labeling showing that weight loss with Xenical (orlistat) delayed the onset of type 2 diabetes in obese patients with impaired glucose tolerance (IGT or pre-diabetes).
The label change is based on results from the XENDOS (Xenical in the Prevention of Diabetes in Obese Subjects) study, the largest and longest study to date of a weight loss medication. XENDOS assessed the delay in onset of diabetes and weight loss in 3304 obese patients (BMI greater than or equal to 30) with either normal (n=2643) or impaired glucose tolerance (n=661) in a four-year, double-blind, placebo-controlled study. Data showed a 42% (p<0.01) relative risk reduction for developing type 2 diabetes among obese patients treated with Xenical who had impaired glucose tolerance at baseline compared to placebo(1). Xenical did not reduce the risk for developing type 2 diabetes among obese patients with normal glucose tolerance at baseline. The XENDOS findings mark the first time that treatment with a weight-loss medication has been shown to prevent or delay the onset of type 2 diabetes. This effect is believed to be due to the additional weight loss that occurs with Xenical treatment, rather than any independent effects of Xenical on glucose or insulin metabolism.
About Weight Loss in the XENDOS Study
- Weight loss, both in the short and long-term, was significantly greater with Xenical than placebo (25.13 lbs. vs. 16.53 lbs.) at one year and (15.21 lbs. vs. 9.04 lbs.) at four years. Following the first year of treatment, almost twice as many Xenical treated patients lost more than 10% body weight (41% vs. 21%), and 73% of patients taking Xenical lost more than 5% body weight versus 45% in patients treated with placebo and lifestyle changes alone. At the end of four years, twice as many Xenical-treated patients lost more than 10% of their body weight (21% vs 10%) and 45% of the patients taking Xenical lost more than 5% of their body weight compared to 28% of the placebo-treated patients.
- Xenical plus lifestyles changes resulted in early and significant improvements in cardiovascular risk factors that were sustained throughout the study, including blood pressure, waist circumference, and lipids (cholesterol). Xenical has not been shown to change cardiovascular outcomes, however.
- Xenical was used safely over four years with more patients completing long-term treatment in the Xenical study group than those undertaking lifestyle changes alone.
Pre-diabetes is a term used to distinguish people who are at increased risk of developing diabetes. People are considered to have pre-diabetes if they have impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). The American Diabetes Association estimates that about 16 million U.S. adults ages 40 to 74 have IGT and 35 million have IFG.
Xenical is indicated for obesity management including weight loss and weight management when used in conjunction with a reduced-calorie diet. Xenical is also indicated to reduce the risk for weight regain after prior weight loss. Xenical is the only available weight-loss medication that works locally in the GI tract to reduce dietary fat absorption by around 30% which effectively promotes weight loss. It is an effective therapy that not only helps patients lose weight, but also helps them maintain their weight loss. The medication is approved for weight management in over 140 countries around the world.
The long-term effects of Xenical on morbidity and mortality associated with obesity have not been established. Because Xenical prevents about one-third of the fat in the food consumed from being absorbed, patients may experience oily spotting or discharge, gas with discharge, fatty or oily stools, increased bowel movements, an urgent need to have them and an inability to control them, particularly after meals containing more fat than recommended. Xenical should not be taken if patients are pregnant, nursing, have food absorption problems or reduced bile flow. If taking cyclosporine, patients should speak to their doctors before taking Xenical. Xenical reduces the absorption of some vitamins. Therefore, a daily multivitamin is strongly recommended. For more information about Xenical visit the web site at www.xenical.com
(1) The percentage of patients with impaired glucose tolerance (IGT) who developed type 2 diabetes was 27.2% for the placebo group (n=62) compared to 18.7% for the orlistat group (n=48) resulting in an absolute risk reduction of 8.5% and a relative risk reduction of 42%; see Xenical prescribing information.
Source: Roche www.rocheusa.com
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
